Core Viewpoint - The article emphasizes the importance of liver health and aims to dispel common misconceptions about hepatitis and liver diseases, particularly in the context of World Hepatitis Day. Group 1: Understanding Hepatitis - Viral hepatitis is contagious and includes types A, B, C, D, and E, with transmission methods varying by type [2] - Non-contagious hepatitis includes alcoholic hepatitis, fatty liver disease, drug-induced hepatitis, and autoimmune hepatitis [2] Group 2: Symptoms and Diagnosis - Symptoms like spider angiomas and palmar erythema can indicate chronic liver disease but are not definitive signs of hepatitis [3] - Many hepatitis patients are asymptomatic, making regular check-ups essential for early detection and treatment [4] Group 3: Treatment and Risk Management - Chronic hepatitis B patients have a 15 to 20 times higher risk of liver cancer, and antiviral treatment can significantly reduce this risk [5] - Patients with liver fibrosis who undergo antiviral therapy for 3 to 5 years can lower their liver cancer risk by 10% to 30% [5] Group 4: Common Misconceptions - Misconception 1: Adults do not need hepatitis B vaccination; high-risk groups should be vaccinated after testing for antibodies [7] - Misconception 2: Hepatitis B cannot be transmitted by mosquito bites; specific conditions are required for transmission [7] - Misconception 3: Liver protection medications do not prevent hepatitis in healthy individuals; they assist those already affected [8]

Market Overview - On June 9, the A-share market saw all three major indices close higher, with the Shanghai Composite Index rising by 0.43% to 3399.77 points, the Shenzhen Component Index increasing by 0.65% to 10250.14 points, and the ChiNext Index up by 1.07% to 2061.29 points. The total trading volume in the Shanghai and Shenzhen markets reached 128.64 billion yuan, an increase of 13.44 billion yuan compared to the previous trading day [1]. Industry Performance - The pharmaceutical sector exhibited the strongest performance on June 9, with chemical pharmaceuticals reaching a nearly four-year high, immunotherapy hitting a two-year high, and weight-loss drugs achieving a one-and-a-half-year high. Other segments such as generic drugs and hepatitis treatments also reached new highs for the year [2]. - In May, at least six domestic innovative pharmaceutical companies announced business development (BD) transactions, primarily involving cross-border cooperation with foreign pharmaceutical companies. Additionally, at the recent ASCO conference, 73 research projects from China were selected for oral presentations, including 11 significant research abstracts [2]. Company Insights - Lingpai Technology, a notable stock on June 9, saw its share price increase by over 10%. The company specializes in the research, production, and sales of new environmentally friendly surface engineering chemicals. In Q1 2025, Lingpai reported an earnings per share of -0.15 yuan and a net profit attributable to shareholders of -26.63 million yuan, with a year-on-year growth rate of 14.54%. The company has completed the research and development of the NCM811 battery chemical system and is actively involved in the new energy vehicle, energy storage, and engineering machinery sectors [4].